Navigation Links
Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
Date:2/17/2009

ticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin and Triapine(R). The Company has filed an NDA with the FDA for Onrigin for remission induction treatment for patients sixty years of age or older with de novo poor-risk AML. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin (laromustine) Injection (formerly Cloretazine (VNP40101M)), delays in the regulatory approval process, particularly for Onrigin (laromustine) Injection, including possible rejection by the FDA of our NDA filing, possible rejection by the FDA of our request for priority review, and possible delays in the FDA' s review process beyond our expectation for approval in the second half of 2009, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
5. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
6. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
7. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
8. Tigris Pharmaceuticals Files IND Application for GGTI-2418
9. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
10. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
11. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Exciting new work by a Florida State University ... that can take your temperature, emit white light, and ... the molecule looks like a butterfly. , Biwu Ma, ... Engineering in the FAMU-FSU College of Engineering, created the ... has continued to discover that his creation has many ...
(Date:8/28/2014)... 2014 PrimeSource Building Products, Inc., ... SoundConnect to support their communication needs ... and web conferencing platform GlobalMeet powered by SoundConnect. ... needs. SoundConnect delivers award winning “results driven” ... Products will be utilizing GlobalMeet powered by ...
(Date:8/27/2014)... 27, 2014 Green & Grow Inc. ... B funding and secured Otter Capital as a significant ... accelerate commercialization of GGI’s Agriplier™ technology, building on recent ... , “Since our first meeting, we have been impressed ... product space,” said Alan Sobba, President and CEO of ...
(Date:8/27/2014)... --  MSC , a healthcare performance improvement company advancing ... of Mary Beth Loesch to President and ... preparing companies for rapid growth and market expansion, Loesch ... Corporate Development and Healthcare. In that role, she oversaw ... as corporate strategy and marketing. Previously, Loesch served as ...
Breaking Biology Technology:Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3MSC names Mary Beth Loesch President and CEO 2
... Inc. and flexcipio s.a. are pleased to ... Clinical Conductor Clinical Trial Management System (CTMS) and ... aligns the industry,s most comprehensive enterprise CTMS, with ... the best tools to optimize efficiency, productivity, and ...
... April 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), ... of a 3-year research agreement with Defence Research ... the preclinical application of IVT,s DepoVax(TM) vaccine formulation ... prevent, prepare for, and respond to biological threats. ...
... Showing Statistically Significant Improvement in Overall Survival -- First ... Data to be Presented at Plenary Session at Upcoming ... Call Today at 9:00 AM ET -SEATTLE, April 14 ... today that the pivotal Phase 3 IMPACT study of ...
Cached Biology Technology:Bio-Optronics Adds Innovative Electronic Data Capture (EDC) Solution to Clinical Conductor Clinical Trial Management System (CTMS), Continues to Improve Workflow and Productivity 2ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canada's Ability to Deal with Biological Threats 2PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 2PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 3PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 4
(Date:8/28/2014)... traditional cigarettes, but still release toxins into the ... , Scientists studying secondhand smoke from e-cigarettes discovered ... particles, with close-to-zero exposure to organic carcinogens. However, ... second-hand e-cigarette smoke were found to be significantly ... of polycyclic aromatic hydrocarbons cancer-causing organic compounds ...
(Date:8/28/2014)... and his collaborators have developed an online analytic tool ... re-engineering cells for biomedical investigation. CellNet is a free-use ... stem cell engineering. Details of CellNet and its application ... papers in the journal Cell . , "This ... all types of cell-based investigations and can potentially offer ...
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research ... for the Genetics Society of America,s 27th Annual ... October 3, 2014 in Pacific Grove, California. ... of students, post doctorates and scientists from underrepresented ... community and to encourage the participation of young ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2New tool aids stem cell engineering for medical research 2
... ITHACA, N.Y. When it comes to potentially doubling the ... may be in the spit. Researchers at Cornell University, ... of Colombia, have discovered that when a major South American ... The secret to this increased yield, they write in the ...
... Mich. Solar power might be nature,s most plentiful and ... lure water insects away from critical breeding areas, a Michigan ... or other methods to break up the polarized reflection of ... likely to deposit eggs on the panels thinking that they ...
... and others interested in the chemical sciences are invited to ... (ACS) Webinars, focusing on tips on how to improve your ... Thursday, June 3, from 2 3 p.m. EDT, the ... for "Effective Technical Writing Short Course" offered by the ACS ...
Cached Biology News:To double spud production, just add a little spit 2Solar panels can attract breeding water insects 2
... The H2OBIT is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. ,A robotic arm rapidly transfers a ... in temperature ramping times that are considerably faster ...
... Dideoxycytidine Dideoxycytidine is a cytidine analog that ... retroviral activity. Immunogen: Chemical / ... The specificity of the ddC antiserum was ... of ddC to moles of ddC analog at ...
... series of Class II Biological Safety ... certification to the world's highest safety ... the cabinets cannot be adjusted out ... low noise and arm rest ensure ...
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
Biology Products: